Analysts Set Cryoport, Inc. (NASDAQ:CYRX) PT at $12.29

Cryoport, Inc. (NASDAQ:CYRX) has received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $12.29.

Several research firms recently weighed in on CYRX. UBS Group lifted their price target on Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, October 18th. Roth Mkm reduced their target price on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, November 8th. Finally, Guggenheim began coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target on the stock.

Cryoport Stock Up 6.4 %

Cryoport stock opened at $8.49 on Friday. The company’s 50-day moving average price is $7.54 and its two-hundred day moving average price is $7.84. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The stock has a market cap of $419.67 million, a P/E ratio of -2.51 and a beta of 1.58. Cryoport has a twelve month low of $5.32 and a twelve month high of $20.10.

Insider Activity

In other news, Director Ramkumar Mandalam sold 7,369 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total value of $54,972.74. Following the sale, the director now directly owns 59,497 shares in the company, valued at approximately $443,847.62. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of Cryoport stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $6.51, for a total transaction of $325,500.00. Following the sale, the chief executive officer now directly owns 731,897 shares in the company, valued at $4,764,649.47. This trade represents a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 109,869 shares of company stock worth $735,673. 10.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Cryoport

A number of hedge funds have recently added to or reduced their stakes in CYRX. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cryoport during the 3rd quarter valued at $82,000. Quest Partners LLC raised its position in Cryoport by 1,083,000.0% in the second quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock valued at $75,000 after purchasing an additional 10,830 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Cryoport during the third quarter valued at about $105,000. Hsbc Holdings PLC acquired a new position in shares of Cryoport in the second quarter valued at approximately $92,000. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Cryoport by 9.5% in the second quarter. The Manufacturers Life Insurance Company now owns 17,683 shares of the company’s stock valued at $122,000 after buying an additional 1,534 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.